
Scientific Breakthrough Technology
The ProLon® Fasting Mimicking Diet® is a nutritional breakthrough that was scientifically developed and clinically tested by Dr. Valter Longo and his team at the Longevity Institute at the University of Southern California (USC).
UCLA lab work
Dr.Longo began his work in Roy Walford’s “calorie restriction” lab at UCLA.
Longo Doctoral Thesis, and USC transition
He completed his doctoral degree under Joan Valentine studying antioxidant enzymes and anti-aging genes. He then began his postdoctoral training in the neurobiology of Alzheimer’s Disease at USC under Caleb Finch.
Publication by Valter Longo touching on the potential for a conserved mechanism from yeast to mammalian neuronal cells on stress resistance and longevity.
Publication for a conserved mechanism, from yeast to humans, on the regulation of longevity and stress resistance.
Publication on case studies for fasting and cancer.
Publication on proof of concept for fasting-mimicking diets in mice and small safety and feasibility trial in humans.
ProLon Launch
L-Nutra officially launched ProLon into the market.
The Longevity Diet Book Published
The culmination of 25 years of research on aging, nutrition, and disease across the globe.
Publication on the fasting-mimicking diet in generally healthy humans.
100,000 unique ProLon users
By 2019, there were more than 100,000 unique ProLon users with some having had done ProLon multiple times over.
Clinical Trials
8 completed, 16 ongoing, and 20 planned.
ProLon Professional Launch
L-Nutra officially launched ProLon® Professional exclusively to healthcare providers.
THE PROLON® FASTING MIMICKING DIET®
No other fasting program has been clinically tested for results or patented for healthy-aging benefits like the ProLon Fasting Mimicking Diet.
By offering this product to your patients, you are helping them maintain metabolic and balance as well as lose excess body fat and promote cellular clean-up for overall rejuvenation.

12,000+
Practitioners
using ProLon

13
Sold in
13 countries

220,000
Patients using
ProLon